Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 17/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 17/20 | 0.45 |
| ▸ | PDK3 | Q15120 | 17/20 | 0.45 |
| ▸ | PDK4 | Q16654 | 17/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31733772 | 0.82 | CA12 (0.39) | PDK1PDK2PDK3PDK4CA12 | |
| SCHEMBL31733487 | 0.82 | CA12 (0.39) | PDK1PDK2PDK3PDK4CA12 | |
| SCHEMBL31733550 | 0.79 | CA1 (0.44) | PDK1PDK2PDK3PDK4CA12 | |
| SCHEMBL2310177 | 0.75 | ESR2 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3799829 | 0.74 | RARA (0.36) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13041657 | 0.74 | ALDH1A1 (0.51) | PDK1PDK2PDK3PDK4CA12 | |
| SCHEMBL7847330 | 0.72 | GPR119 (0.33) | PDK1PDK2PDK3PDK4CA12 | |
| SCHEMBL21973574 | 0.72 | ALDH1A1 (0.44) | PDK1PDK2PDK3PDK4MAPT | |
| SCHEMBL25604137 | 0.72 | ESR1 (0.48) | — | |
| SCHEMBL2616853 | 0.71 | CA12 (0.44) | PDK1PDK2PDK3PDK4CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025237891-A1 | QUINOLINE-2-CARBOXAMIDE DERIVATIVES AS RAD51 INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-11-20 | — | — | WO | disclosed |